Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Juan Raúl García"'
Autor:
Oscar Daniel Ayala, Daisy Banta, Mariam Hovhannisyan, Liliana Duarte, Alfonso Lozano, Juan Raúl García, Patricia Montañés, Simon W. Davis, Felipe De Brigard
Publikováno v:
NeuroImage: Clinical, Vol 34, Iss , Pp 103033- (2022)
Multiple sclerosis (MS) is a progressive disease characterized by widespread white matter lesions in the brain and spinal cord. In addition to well-characterized motor deficits, MS results in cognitive impairments in several domains, notably in episo
Externí odkaz:
https://doaj.org/article/2eb415915683404ba1c13709cf17d258
Autor:
Juan Raúl García Bonitto, Diana González-Bravo, Laura Prieto-Pinto, Laura van der Werf, Camilo Castañeda-Cardona
Publikováno v:
Acta Neurológica Colombiana, Vol 36, Iss 3 (2020)
INTRODUCTION: Natalizumab is a humanized monoclonal antibody prescribed in the treatment of multiple sclerosis, the most prevalent chronic and inflammatory disease of the central nervous system (CNS). NEDA (no evidence of disease activity) status is
Externí odkaz:
https://doaj.org/article/d84448b965444a189c08cf76bd79ec71
Publikováno v:
Multiple sclerosis and related disorders. 61
Physical disability, cognitive impairment, depression, and fatigue are poorly understood in Latin American patients with multiple sclerosis following alemtuzumab infusion.To describe Sustained changes in physical disability in an average 22-month fol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cbe4770747a57a33d3f19c6f0835089f
https://pubmed.ncbi.nlm.nih.gov/35397291
https://pubmed.ncbi.nlm.nih.gov/35397291
Autor:
Camilo Castañeda-Cardona, Laura van der Werf, Diana González-Bravo, Juan Raúl García Bonitto, L. Prieto-Pinto
Publikováno v:
Acta Neurológica Colombiana, Volume: 36, Issue: 3, Pages: 120-124, Published: 11 JUN 2020
SUMMARY INTRODUCTION: Natalizumab is a humanized monoclonal antibody prescribed in the treatment of multiple sclerosis, the most prevalent chronic and inflammatory disease of the central nervous system (CNS). NEDA (no evidence of disease activity) st
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a764d27e4da25df3f489138071b264a
http://www.scielo.org.co/scielo.php?script=sci_arttext&pid=S0120-87482020000400120&lng=en&tlng=en
http://www.scielo.org.co/scielo.php?script=sci_arttext&pid=S0120-87482020000400120&lng=en&tlng=en
Autor:
Judith Steinberg, Yara D. Fragoso, Juan Carlos Duran Quiroz, Juan Raul García, Caroline Guerra, Virginia Rodriguez, Claudia Carcamo Rodriguez, Ethel Ciampi, Edgar Correa-Diaz, Miguel Macías, Nelson Novarro, Darwin Vizcarra, Carlos Oehninger Gatti, Geraldine Orozco, Adriana Carrá
Publikováno v:
Neurology and Therapy, Vol 8, Iss 2, Pp 207-214 (2019)
Abstract The use of biosimilar drugs for multiple sclerosis (MS) has become widespread in Latin America, with the goal of reducing costs of treatments, promoting the sustainability of healthcare systems, and improving patient access to these therapie
Externí odkaz:
https://doaj.org/article/0baf7f7db303413a982ec6797fe80f85
Publikováno v:
Multiple Sclerosis & Related Disorders; May2022, Vol. 61, pN.PAG-N.PAG, 1p
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.